Seeing as how the penny stock of OncoSec Medical Inc. (ONCS) set a new 52 week high before ending Thursday’s session at 0.532, up +195% since our initial alert, with dollar volume of $3,053,064, paying attention to when AV Therapeutics, Inc. (AVTH) begins trading would be a smart thing to do. The development stage cancer therapeutics focused company executed a 70-for-1 split back on June 25, 2013 and announced yesterday that AVTH stock was now trading on the OTCQB. Expecting “BIG” announcements of their Capridine phase I clinical trials later this quarter, it should be less than a week now from when promotional activity begins now that the share price has come down to a more reasonable entry level.
Our Next Pick Is Coming Soon!
Click HERE To Make Sure You Don’t Miss Any Of Our Hot Penny Stock Alerts!
AVTH Stock Quote
Market Cap: 41.30M
Last: 0.61 ▼ -1.39 (-69.50%)
Issued and Outstanding: 84,000,000
All officers and directors as a group: 49,919,301
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
January is biotech month and what better time for some “Maverick” type promotion to begin on AV Therapeutics. The once Aquino Milling Inc., incubated under the legal guidance of Jonathan D. Strum, has all the right stuff a company requires that’s in need of funds to begin their quest to cure cancer.
AV Therapeutics has te exclusive rights to 5 U.S. patents which deal with Nitroacridines and Immunotherapy. Nitroacridines have been shown to have potent antitumor capabilities against mammalian tumors and are potent DNA-binding and cytotoxic agents in cancer cells, but have not been widely pursued as a potential cancer vaccine due to their high systemic toxicity. AV Therapeutics has developed a certain Nitroacridine, designated “C-1748”, which, in a prostate cancer-specific preclinical study on rodents, has proven to have markedly lower levels of toxicity compared with its parent making C-1748 is a unique cancer drug which is specific to prostate cancer cell types, and which lacks systemic toxicity.
On Friday, AVTH stock was brought down to a level which makes entering into a pre-promotion position tempting. There’s only about 34 million shares in the float and rumors of a January 14 launch date means those who actively monitor the AVTH situation this week, watching for which market maker gets on the bid/ask, should be an early hint for those who play pre-promos.
Since the target for AV Therapeutics is to raise around $10,000,000 so that they can get their chemotherapeutic drug called Capridine, the prostate cancer specific drug and a prostate cancer vaccine, into Phase I clinical trials in humans within the next 12 to 18 months, look for AVTH to be a slow, steady climber throughout January.
About AVTH Stock
AV Therapeutics, Inc., aka Applied Vaccines Therapeutics, LLC, is a development stage biotechnology company engaged in the business of developing cancer therapeutics and immunotherapeutic vaccines to treat active disease and to prevent metastases and recurrence.
Penny stocks promoted in early January by major campaigns almost always tend to bring home the bacon and a couple of loaves of bread with it. Last year’s GNIN and ECAU fell flat after February came around, but if AVTH can match them, 200% gains should be a no-brainer as long as no hard-mails are sent out. If AVTH stock is mailed out on those glossy brochures grandma and grandpa always seem to receive in the mail, selling before the SEC halt will be a smart thing to do.
Our Next Pick Is Coming Soon!
Text Keyword “AIMHIGH” To 99000 To Make Sure You Don’t Miss It!